Sigma-Aldrich Signs RNAi Pact with Genospectra

Sigma-Aldrich has signed a series of agreements that expands its position in the areas of RNA Interference (RNAi), gene expression and cell-based assays. Sigma-Aldrich and Genospectra, a developer of products to support systems biology and drug discovery efforts, have signed several agreements in which Sigma-Aldrich acquires a minority equity stake in Genospectra and is granted access to various Genospectra technologies.

Under the terms of the agreement, Sigma-Aldrich gained access to the QuantiGene gene expression profiling assay and Genospectra’s technologies for inducible siRNA, a unique nano-particle system for delivery of siRNA and other biomolecules to cells. The companies will participate in a joint program to develop new technology and products in the area of cell-based assays.

Sigma-Aldrich will also receive licenses to commercialize the inducible siRNA and delivery technologies and distribution rights to the QuantiGene product line. The two companies will participate in a joint development program for cell-based assays, particularly to develop novel live cell biosensor assay reagents. These reagents provide real-time data on protein activity and location in living cells, and will make an impact in the High Content Screening and Cell-Based Assay fields.

“We are very pleased to enter into this relationship with Genospectra,” said Shaf Yousaf, president of Sigma-Aldrich’s Research Biotech business unit. “These agreements strengthen our already strong portfolio of products in the areas of RNA Interference and RNA profiling. Just as importantly, the Genospectra biosensor technology and research collaboration form the foundation for future product development in the rapidly growing area of cell- based assays.”

Dr. Frank Witney, Genospectra’s chief executive officer, said, “We are delighted with Sigma-Aldrich’s decision to invest and partner with Genospectra. Sigma is an important player in the life sciences reagents space, so this new relationship validates both Genospectra’s strategy and portfolio, and will drive both companies’ programs in novel areas such as biosensors and cell based assays.”